Updated:
Silo Pharma, Inc.
Silo Pharma is a family office investing in pharmaceuticals and biotech, focused on early-stage drug development and intellectual property.
Silo Pharma, Inc.
Silo Pharma, Inc. is a family office entity that operates in the pharmaceutical and biotechnology sectors. Its founding year and founding principal are not publicly available. The family office's wealth origin and total scale remain undisclosed. The firm focuses on direct investments in drug development and related intellectual property. Silo Pharma targets early-stage therapeutic compounds and has been involved in clinical-stage programs. The geographic footprint appears to be US-based. No named portfolio companies or co-investors are confirmed in public records. Total deployment and professional team size are not publicly reported. No additional offices, adjacent vehicles, or recent operational events are documented. Silo Pharma does not disclose philanthropic structures or club memberships. The structural differentiator, if any, is the firm's concentration on pharmaceutical IP and biotech development, which may distinguish it from diversified family offices. However, the lack of public information limits further assessment. (public record)
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at Silo Pharma?
The individual or team making investment decisions at Silo Pharma is not disclosed in public records. The family office does not publish a leadership page or list of professionals.
How does Silo Pharma source proprietary deal flow?
Silo Pharma's deal sourcing methods are not publicly described. Given its focus on pharmaceutical IP and drug development, the firm may rely on internal research or partnerships, but this is not confirmed.
Is Silo Pharma structured as a single family office or does it operate more like a venture firm?
Silo Pharma is a single-family office, based on its name and public filings. It does not appear to operate as a multi-family office or external venture fund. Its capital is likely deployed for a single family's benefit.
Does Silo Pharma participate in fund commitments or only direct deals?
Public records do not specify whether Silo Pharma commits capital to external funds or exclusively makes direct investments. Its known activity centers on direct pharmaceutical and biotech investments.
What investment stages does Silo Pharma typically target?
Silo Pharma is known to target early-stage drug development and clinical-stage programs. The firm invests in intellectual property and therapeutic compounds at pre-commercial stages.
Where does the underlying wealth come from?
The origin of the wealth managed by Silo Pharma is not publicly disclosed. The family and industry background remain private.
Does Silo Pharma maintain philanthropic structures, and how are they separated?
There is no public record of separate philanthropic structures associated with Silo Pharma. The family office appears to operate solely as an investment vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: